Zoetis
As on 18 Apr, 2026 | 01:29 IST
| Open | 119.57 |
| Previous Close | 119.04 |
| Beta | 0.46 |
| High | 122.97 |
| Low | 119.92 |
| TTM EPS See historical trend | 6.42(+8.45% YoY) |
| 52 Week High | 172.02 |
| 52 Week Low | 113.31 |
| TTM PE See historical trend | 19.07(Low PE) |
| Mkt. Cap ($ Billion) | 56.05 |
| Dividend Yield | 1.61 |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 120.74 |
| 10 | 119.63 |
| 20 | 117.98 |
| 50 | 121.93 |
| 100 | 122.84 |
| 200 | 134.52 |
Returns
| 1 Week | 3.82% | |
| 1 Month | 0.67% | |
| 3 Months | -1.79% | |
| YTD | -2.70% | |
| 1 Year | -17.63% | |
| 3 Years | -29.89% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 926.70 | 2.51 | 881.48 | 38.30 | 24.21 | 0.58 | 1,133.95/623.99 | -0.39 | Neutral |
| J&J | 234.18 | -0.15 | 564.23 | 21.68 | 10.80 | 2.50 | 251.71/146.13 | -1.67 | Bearish |
| AbbVie | 208.38 | -0.29 | 368.20 | 20.84 | 10.00 | 2.91 | 244.80/168.66 | -5.19 | Very Bearish |
| Merck | 119.07 | 3.13 | 301.56 | 13.27 | 8.97 | 3.12 | 125.14/73.35 | 2.76 | Bullish |
| Pfizer | 27.56 | 1.25 | 156.06 | 8.53 | 3.23 | 6.91 | 28.74/21.89 | 0.33 | Bullish |
Market news
- Wall St ends mixed, notches weekly gains as investors parse Middle East negotiationsApril 11, 2026 8:53 AM
- Wall Street skids as Middle East turmoil fans inflation fearMarch 21, 2026 9:02 AM
- Wall Street closes lower, posts weekly loss as war on Iran fuels inflation worriesMarch 14, 2026 8:59 AM
- US stocks close down as oil spikes 12%, job market weakensMarch 7, 2026 9:27 AM
About the company
Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision livestock farming technology. The Company has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers.